Myeloproliferative Neoplastic Diseases Observatory From Brest (OBENE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02897297|
Recruitment Status : Recruiting
First Posted : September 13, 2016
Last Update Posted : January 17, 2018
All patients diagnosed or followed in Brest University Hospital for Philadelphia negative MPNs will be included in this observational study.
MPNs recorded included: polycythemia vera (PV), essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF).
This is a not interventional study. Alive patients need to sign a non-opposition consent form.
Patients will be followed until last news (death, change of reference centre...).
|Condition or disease|
|Polycythemia Vera Essential Thrombocythemia Primary Myelofibrosis|
In this retrospective and prospective study, clinical and biological data from diagnosis until last news will be recorded.
Clinical data collected: patients and disease characteristics at the time of the diagnosis, disease and mutational status, cardio-vascular risk factors, history of thrombosis and cancer.
Biological data collected: hemogram and bone marrow results if available. During the follow-up new data will be noted: treatment changes (reasons of change and type of drug), thrombotic events (localization, date and hemogram), phenotypic evolutions (type and date), death (date and etiology).
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Observatoire Brestois Des Néoplasies Myéloprolifératives|
|Study Start Date :||September 2015|
|Estimated Primary Completion Date :||September 2025|
|Estimated Study Completion Date :||September 2025|
- Overall Survival [ Time Frame: twenty years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02897297
|Contact: Jean-Christophe Ianotto||jean-christophe.Ianotto@chu-brest.fr|
|CHRU de Brest||Recruiting|
|Brest, France, 29609|
|Contact: Jean-Christophe Ianotto, MD|
|Contact: Eric Lippert, MD-PhD|
|Study Director:||Jean-Christophe Ianotto||CHRU de Brest|